Related references
Note: Only part of the references are listed.Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience
Katharine L. Lewis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections
Rossana Maffei et al.
BLOOD REVIEWS (2020)
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival
Nicolas Martinez-Calle et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis
Eliza M. Lauer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis
Kelu Hou et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use
Feili Chen et al.
CANCER MEDICINE (2020)
Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence
Elisa Santambrogio et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Primary central nervous system lymphoma: Novel precision therapies
Patrizia Mondello et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
C. Soussain et al.
EUROPEAN JOURNAL OF CANCER (2019)
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma
Christian Grommes et al.
BLOOD (2019)
Introduction of novel agents in the treatment of primary CNS lymphoma
Christian Grommes et al.
NEURO-ONCOLOGY (2019)
Ibrutinib brain distribution: a preclinical study
Lauriane Goldwirt et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Michail S. Lionakis et al.
CANCER CELL (2017)
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
Carsten U. Niemann et al.
CLINICAL CANCER RESEARCH (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Sample size calculation for the one-sample log-rank test
Jianrong Wu
PHARMACEUTICAL STATISTICS (2015)
Sample size calculation for the one-sample log-rank test
Rene Schmidt et al.
STATISTICS IN MEDICINE (2015)
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
Sarah E. M. Herman et al.
BLOOD (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas
Agnieszka Korfel et al.
HAEMATOLOGICA (2013)
Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials
Jennifer R. Brown
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy
N. B. Khimani et al.
ANNALS OF ONCOLOGY (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
Andres J. M. Ferreri et al.
LANCET (2009)
Methodological index for non-randomized studies (MINORS):: Development and validation of a new instrument
K Slim et al.
ANZ JOURNAL OF SURGERY (2003)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
